Cart $0.00 (0)
 
 
Free Sample

NEW! TransIT-VirusGEN® SELECT Transfection Reagent

Large Scale Virus Production for Preclinical and Early Phase Clinical Trials

To inquire about bulk pricing, please call 888-530-0801
International inquiries please call +1-608-441-2852
Return Policy

Select a Size:

MIR 673030 ml

Catalog number selected: -

-

Generate a Quote

All TransIT-VirusGEN® reagents are designed to enhance delivery of packaging and transfer vector DNA to suspension and adherent HEK 293 cell types in order to increase production of recombinant lentivirus and adeno-associated virus (AAV).

 

TransIT-VirusGEN® SELECT Transfection Reagent is identical in formulation to our research-grade TransIT-VirusGEN® and includes release testing and quality documentation to streamline the process of ancillary material* qualification, ensuring seamless transitions from discovery through large-scale manufacturing.

 

With performance that exceeds PEI and PEIpro® reagents, TransIT-VirusGEN® SELECT offers a simplified, cost-effective workflow, making it the superior choice for large-scale virus production.

 

*USP <1043> ANCILLARY MATERIALS FOR CELL, GENE AND TISSUE-ENGINEERED PRODUCTS

 

  • Performance  Efficient DNA delivery for large-scale production of high-titer viral vectors 
  • Quality – Tested for performance, identity, sterility, endotoxin and mycoplasma
  • Reliability – Exceptional lot-to-lot consistency   
  • Flexibility – Compatible with different virus production platforms and repeat filtration
  • Animal Origin Free – Fully synthetic transfection reagent formulation
    [Example Certificate of Origin | Example Certificate of Analysis | 

    Example BSE TSE Statement]
Sample Now
 

TransIT-VirusGEN® Product Family

TransIT-VirusGEN Biotherapeutic Pipeline

Sample TransIT-VirusGEN® SELECT Transfection Reagent for gene and cell therapy manufacturing

Sample TransIT-VirusGEN® Transfection Reagent for research and development

Figures and Data

Copy Link Enlarge Image
TransIT-VirusGEN SELECT Suspension and Adherent PEI Comparison

TransIT-VirusGEN® SELECT Outperforms Competitor 25 kDa linear PEI and PEIpro® Transfection Reagents in Suspension and Adherent Cell Culture Systems. 
Lentivirus was produced using (A) suspension FreeStyle™ 293-F cells grown in FreeStyle™ F17 Medium or (C) adherent 293T/17 cells grown in DMEM + 10% FBS and transfected with 3rd generation vectors pLKO.1-puro-CMV-TurboGFP™ transfer vector (Sigma) and ViraSafe™ Pantropic Packaging mix (pRSV-Rev, pCMV-VSV-G, pCgpV, Cell Bio Labs) at a 3:0.5:0.5:2 DNA ratio, 1 μg/ml total plasmid DNA, using the TransIT-VirusGEN® SELECT Transfection Reagent (3:1, vol:wt), 25 kDa linear PEI (4:1, Polysciences) or PEIpro® (2:1, Polyplus Transfection). Virus-containing supernatant was used to transduce 293T/17 cells and GFP expression was measured at 72 hours post-transduction using a Guava® easyCyte™ 5HT Flow Cytometer.

AAV2 was produced using (B) suspension FreeStyle™ 293-F cells grown in FreeStyle™ F17 Medium or (D) adherent 293T/17 cells grown in DMEM + 10% FBS and transfected using pAAV-hrGFP, pAAV-RC, and pAAV-Helper plasmids (1:1:1 DNA ratio, 1.5 μg/ml plasmid DNA, Agilent Technologies) using TransIT-VirusGEN® SELECT Transfection Reagent (2:1, vol:wt), 25 kDa linear PEI (2:1, Polysciences) or PEIpro® (2:1 or 4:1, Polyplus Transfection). Harvested virus was used to transduce HT1080 cells and GFP expression was measured 48 hours post-transduction using a Guava® easyCyte™ 5HT Flow Cytometer. For both lentivirus and AAV, functional titers were measured from virus dilutions with less than 20% GFP positive cells. The error bars represent the range of triplicate wells.

Copy Link Enlarge Image
TransIT-VirusGEN SELECT Lot-to-Lot Variability
Lot-to-Lot Consistency with the TransIT-VirusGEN® SELECT Transfection Reagent.
(A) Lentivirus was produced using suspension FreeStyle™ 293-F cells grown in FreeStyle™ F17 Medium and transfected with 3rd generation vectors pLKO.1-puro-CMV-TurboGFP™ transfer vector (Sigma) and ViraSafe™ Pantropic Packaging mix (pRSV-Rev, pCMV-VSV-G, pCgpV, Cell Bio Labs) at a 3:0.5:0.5:2 DNA ratio, 1 ug/ml total plasmid, using the TransIT-VirusGEN® SELECT Transfection Reagent (3:1, vol:wt). Virus containing supernatant was used to transduce 293T/17 cells and GFP expression was measured at 72 hours post-transduction using a Guava® easyCyte™ 5HT Flow Cytometer.

(B) AAV2 was produced using suspension FreeStyle™ 293-F cells grown in FreeStyle™ F17 Medium and transfected using pAAV-hrGFP, pAAV-RC, and pAAV-Helper plasmids (1:1:1 DNA ratio, 1.5 µg/ml, Agilent Technologies) using TransIT-VirusGEN® SELECT Transfection Reagent (2:1, vol:wt). Harvested virus was used to transduce HT1080 cells and GFP expression was measured 48 hours post-transduction using a Guava® easyCyte™ 5HT Flow Cytometer. For both lentivirus and AAV, functional titers were measured from virus dilutions with less than 20% GFP positive cells. The error bars represent the standard deviation of triplicate wells.
Copy Link Enlarge Image
TransIT-VirusGEN SELECT Multiple Filtrations

TransIT-VirusGEN® SELECT Transfection Reagent can be Filtered Multiple Times with No Effect on Reagent Performance. 
(A) Lentivirus was produced using suspension FreeStyle™ 293-F cells grown in FreeStyle™ F17 Medium and transfected with 3rd generation vectors pLKO.1-puro-CMV-TurboGFP™ transfer vector (Sigma) and ViraSafe™ Pantropic Packaging mix (pRSV-Rev, pCMV-VSV-G, pCgpV, Cell Bio Labs) at a 3:0.5:0.5:2 DNA ratio, 1 ug/ml total plasmid, using the TransIT-VirusGEN® SELECT Transfection Reagent (3:1, vol:wt) that was filtered through a 0.22 um polyethersulfone (PES) filter unit (Millipore Sigma) for the indicated number of times. Virus-containing supernatant was used to transduce 293T/17 cells and GFP expression was measured at 72 hours post-transduction using a Guava® easyCyte™ 5HT Flow Cytometer.

(B) AAV2 was produced using suspension FreeStyle™ 293-F cells grown in FreeStyle™ F17 Medium and transfected using pAAV-hrGFP, pAAV-RC, and pAAV-Helper plasmids (1:1:1 DNA ratio, 1.5 µg/ml, Agilent Technologies) using TransIT-VirusGEN® SELECT Transfection Reagent (2:1, vol:wt). Harvested virus was used to transduce HT1080 cells and GFP expression was measured 48 hours post-transduction using a Guava® easyCyte™ 5HT Flow Cytometer. For both lentivirus and AAV functional titers were measured from virus dilutions with less than 20% GFP positive cells. The error bars represent the standard deviation of triplicate wells.

 
Copy Link Enlarge Image
Higher Titer Efficiency with TransIT-VirusGEN Over PEI for Lentivirus Generation

Higher Transfection Efficiency with TransIT-VirusGEN® Over PEI for Lentivirus Generation. HEK293T/17 cells were transfected with lentiviral packaging plasmids and either (a) control RFP transfer plasmid or (b) targeting SPdCas9-RFP transfer plasmids using either TransIT-VirusGEN® Transfection Reagent (3:1 reagent to DNA ratio; vol:wt) or 25 kDa linear PEI (3:1 reagent to DNA ratio; wt:wt). Brightfield and RFP Images were taken 17-22 hours post-transfection.

Data courtesy of Zuzana Drobna, PhD (Dr. Keung's Lab), Department of Chemical and Biomolecular Engineering,  North Carolina State University

Resources

For a Certificate of Origin (COO) and/or Certificate of Analysis (COA) for this product, please contact techsupport@mirusbio.com.

NEW! Virus Titer Reference Card: Methods to Measure Lentivirus and Adeno-associated Virus in Your Sample

Specifications

Storage Conditions:
All Configurations: Store at -10 to -30°C

Product Guarantee:
All Configurations: 6 months

Technical Product Literature


Additional Resources

Testimonials

Our lab is interested in identifying barriers to influenza virus cross-species transmission and how those control the emergence of new pandemic viruses... we were able to use TransIT®-LT1 in our studies to further implicate the viral polymerase complex as a major regulator of viral tropism and identify new adaptive strategies used by influenza as it moves from birds to people. Details of these efforts can be found in the Journal of Virology. (Mehle, A et al. Journal of Virology. Feb 2012)
Dr. Andrew Mehle
University of Wisconsin - Madison
We routinely use muscle cells which are very difficult to transfect. We recently tested TransIT-X2® from Mirus. With TransIT-X2®, we obtained a transfection rate between 30-40% for transfection of myoblasts using a 2:1 reagent (µl) to DNA (µg) ratio. We will continue to use TransIT-X2® for the transfection of our muscle cells.
Fannie Semprez
CNRS-UMR8003 - Saints-Pères Paris Institute for the Neurosciences
We work on non-small cell lung cancer (NSCLC) which is an adherent cell culture line. Previously, we have tested many transfection products from several companies without much success, but the TransIT-X2® Dynamic Delivery System works very well with NSCLC using my protocol.
Dr. Luo Wang
University of Michigan Comprehensive Cancer Center
Our lab tested TransIT®-Insect for virus production in Sf9 cells. It performed better than Cellfectin® II that we currently use for transfecting these cells. Cytopathic effects (CPE) of the baculovirus were observed after 5 days with as little as 0.5 µg DNA per well of a 6-well plate. When using Cellfectin® and other reagents, we haven't seen any results using the same amount of input DNA.
Eric Carlin
Florida Gulf Coast University
Our lab has used TransIT®-LT1 for a long time and we have observed good transfection efficiency with less toxicity compared to other transfection reagents we have used, but I was not aware Mirus had such a wide range of transfection reagents. We received a sample of TransIT®-mRNA from Mirus for the transfection of viral RNA, and I am very pleased with this product. Moving forward I will look to Mirus for various transfection reagents.
Luke Bussiere
Iowa State University
Our lab recently used theTransIT-mRNA Transfection Kit to show that intracellular delivery of HPLC-purified and pseudouridine-containing mRNA can translate very efficiently without immune activation which is ideal for mRNA-based gene therapy applications. TransIT®-mRNA further facilitated this work through low toxicity transfections of HEK 293T, human dendritic cells (DCs) and primary keratinocytes. (Karikó et al. Nucleic Acids Research, 39:e142, 2011)
Dr. Katalin Kariko
University of Pennsylvania - Department of Neurosurgery
In our hands, we achieved greater than 80% target knockdown and observed lower toxicity when transfecting NCI-295R cells with TransIT-siQUEST® than with Lipofectamine®. Results we obtained using TransIT-siQUEST® are included in our recent publication demonstrating that the nuclear antigen-associated factor KIAA0101 is implicated in adrenal cancer growth and invasion. (Jain, M et al. PLoS ONE. 2011;6(11):e26866. Epub 2011 Nov 11)
Dr. Meenu Jain
Laboratory of Electron Kebebew - National Institutes of Health
In our lab we used TransIT®-mRNA with EGFP mRNA as a control for transfection efficiency in the Sf9 insect cell line. Transfection efficiency was higher than 90%. (Hera BioLabs)
Dr. Valeriya Steffey, M.D.
Director of In-Vitro Studies at Hera BioLabs
I was using Lipofectamine® to transfect HEK cells and was only getting about 20% transfection rates but after using TransIT®-2020 it went from 20% to 70%! I highly recommend using this reagent. It was very easy to follow the protocol and I obtained high cell viability. (Review published in SelectScience)
Dr. Olivia George
Univeristy of New Mexico - Department of Molecular Genetics and Microbiology
Our lab tested TransIT®-LT1 from Mirus for virus production in 293T cells. At a 3:1 ratio using up to 5 µg of lentivirus, packaging and envelope plasmid, TransIT®-LT1 was far superior to Lipofectamine® in terms of viral titer downstream. So much so that our lab purchased the 0.4 ml product after using the trial.
Andrew Paluch
University of Cincinnati
TransIT®-2020 Transfection Reagent has been working well in our CRISPR genome editing experiments in HEK 293 cells. I appreciate the fact that the transfection protocol is straightforward, the toxicity appears to be low and we obtained high CRISPR knockout efficiency.
Steve Plouffe
Sanford Consortium for Regenerative Medicine
We recently tested the TransIT-X2® Dynamic Delivery System head-to-head against Lipofectamine® 2000 for DNA transfection of NIH-3T3 fibroblasts and the breast cancer cell line ZR-75-1. We observed higher efficiency and less toxicity when using TransIT-X2®. We are also pleased to hear that TransIT-X2® will be offered in similar volume configurations to Lipofectamine® 2000.
Dr. Edwin Li
Saint Joseph's University
Recently, Mirus Tech Support helped me troubleshoot moving my virus production to a serum free procedure. They helped me with many aspects of the procedure as I am new to this field. Most importantly, they alerted me that the media I was using for my transfections was recently identified by the R&D team at Mirus as not being appropriate for transfections. Once I changed transfection media, I was able to produce virus in my serum free system. Thank you to Mirus Tech Support. Your support is greatly appreciated.
Ann Wrightstone
Sigma Aldrich
Our lab has been satisfied with the routine use of the TransIT-HeLaMONSTER® Transfection Kit. Transfections exhibit high target protein expression with very little cell toxicity. Cells remain viable post-transfection and can be readily infected with virus without any problems.
Dr. Corine St. Gelais
The Ohio State University – Center for Retrovirus Research
TransIT®-CHO is a great product. Easy to use, works well, and reasonably priced.
Matthew Nicotra
University of Pittsburgh
Excellent technical support, they are very knowledgeable.
He Song Sun
University of Toronto Scarborough - Cell and Molecular Biology
Our lab regularly transfects head and neck cancer squamous carcinoma cell lines as well as pre-cancerous oral lesion cell lines and primary cells with Mirus Bio products. We recently published a paper using Mirus Bio TransIT®-LT1 in which we concluded tobacco carcinogens up-regulate AP-1 activity and AP-1 dependent IL-8 and VEGF gene expression in head and neck cancer. (Swenson, W et al. Molecular Carcinogenesis. April 2011)
Beverly Wuertz
Ondrey Lab, University of Minnesota
Mirus Bio donated transfection reagents and provided a guest lecture on the fundamentals of transfection as part of our Biotechnology Training Program. Students in our Cell Culturing Course used the donated Mirus reagents to deliver a pCMV-CAT plasmid to COS-7 cells for subsequent detection by ELISA. The transfection experiments went very well—the students understood the methods, and the transfected cells showed high levels of CAT expression. We plan to include this teaching laboratory module again next year.
Joseph Lowndes, Ph.D.
Madison College Biotechnology Program
I'm working with primary cells that are difficult to transduce, so I need to optimize my virus yield to ensure I get enough infection. The TransIT®-293 reagent is now going to be a permanent part of my arsenal.
Matt Lowrey
University of Iowa, Diana Zepeda
We were pleased with the performance and low toxicity of the TransIT-X2® Dynamic Delivery System when transfecting our renal carcinoma cell line 786-0.
Sathish Padi
North Dakota State University
Using TransIT®-2020, we transfected HeLa cells in 6-well plates with 1.25 µg of the Zheng lab construct (pX330) from Addgene that harbors both a specific guide RNA against a recognition sequence in our gene of choice, and 1.25 µg of a donor plasmid with 1 kb of 5’ and 3’ homology sequence. We then selected the cells using puromycin and came across a population that harbored the modification we were interested in. Thank you so much for the sample of TransIT®-2020. Mirus has always been without exception the gold standard for me and why anyone else would want to use anything else is just beyond me.
Aviva Joseph
University of Massachusetts Medical School
I am definitively getting better transfection efficiency with TransIT-VirusGEN® but more important, a higher level of transduced cells afterwards. Of course, efficiency depends on backbone and transgene features, but I am very satisfied.
Dr. Zuzana Drobna
North Carolina State University
I was very depressed for the last 6 months because I was unable to transfect my rat cell line with various transfection reagents. I tried 5 Nucleofection® programs, 2 buffers and several different cell densities. But nothing worked. I am very happy to inform you, Ingenio® is a life saver!
Sanal Madhusudana Girija
Albert Einstein College of Medicine
Our lab routinely uses Mirus Bio transfection products, and we recently published using TransIT-siQUEST® to perform RNA interference experiments in LNCaP cells to elucidate the role of p53 in selenium-induced apoptosis in prostate cancer cells. These results were published in 2010 in the International Journal of Oncology. (Sarveswaran, S. et al. IJO. Jan 2010)
Dr. Jagadananda Ghosh
Henry Ford Health System - Vattikuti Urology Institute
Our lab routinely works with primary human fibroblasts which are notoriously difficult to transfect, and we require a method that is non-toxic, reliable, and reproducible. TransIT®-2020 is the only reagent on the market that fits those criteria. In addition, TransIT®-2020 also transfects colon cancer cell lines HCT-116 and DLD1 with much higher efficiencies. Overall, the pace and quality of our research have improved since we started using TransIT®-2020.
John A. Burns
David Scicchitano Lab, New York University
I recently tested TransIT®-2020 and TransIT®-LT1, and both reagents worked well in terms of their efficiency at transfecting human-derived iPS cells with CRISPR constructs and a fluorescent protein reporter. Through visual inspection, transfection efficiencies with TransIT®-2020 and TransIT®-LT1 were clearly higher than with Lipofectamine® 3000.
Fedir Kiskin
University of Cambridge
We routinely use Mirus TransIT®-LT1 Transfection Reagent for the delivery of plasmid DNA to carry out immunoprecipitation experiments. Our lab recently published using TransIT®-LT1 for this application to reveal a crucial regulator (MCUR1) for calcium uptake in the mitochondria to regulate cellular metabolism. (Mallilankaraman, K et al. Nature Cell Biology. December 2012)
Dr. Karthik Mallilankaraman
Madesh Lab, Temple University
...We have been able to transfect BMDM’s with the TransIT®-2020 Transfection Reagent. Not only are my cells healthier, but I get good expression, and it is more cost effective to the Neon Transfection System that my lab traditionally uses. I have also been able to share these results with others that are now trying it with great success. It makes me look like a hero!
Jeffrey Fay
Hoffman Lab, University of Hawaii at Manoa
The TransIT-X2® Dynamic Delivery System outperformed all other transfection reagents we have tested for DNA transfection of our C2C12 mouse myoblast cell line. In addition, TransIT-X2® was also less toxic.
Dr. Guangwei Du
Texas Medical Center
I recently tested TransIT®-2020 and TransIT®-LT1, and both reagents worked well in terms of their efficiency at transfecting human-derived iPS cells with CRISPR constructs and a fluorescent protein reporter. Through visual inspection, transfection efficiencies with TransIT®-2020 and TransIT®-LT1 were clearly higher than with Lipofectamine® 3000.
Fedir Kiskin
University of Cambridge
I have been using the Ingenio® Electroporation Solution to generate knockouts using the CRISPR/Cas system in primary neural stem cells. The transfection efficiency is comparable to the Amaxa® kit, and knockout generation is quite efficient using wt-Cas9 plasmids. Multiple gRNAs have yielded comparable efficiency.
Simon Weissman
Biotech Research and Innovation Centre, Denmark
Mirus sent me samples of TransIT-VirusGEN® to test with 293T cells to generate lentivirus. It outperforms the transfection reagent I was using before. The protocol is really simple, and the transfections are robust. I’m getting great virus production.
Dr. Steve Williams
Xyphos Inc.
We recently engineered a bispecific immunofusion for the treatment and elimination of leukemia stem cells. For this work we chose TransIT-PRO® for antibody production in CHO-S cells based on the high protein yield we obtained. (Kuo et al. Protein Eng Des Sel. 2012 Oct;25(10):561-9. Epub 2012 Jun 27)
Jen-Sing Liu, Ph.D.
Molecular Templates Inc.
Our lab successfully tested TransIT®-Insect Transfection Reagent for generating recombinant baculovirus in insect cells. Using TransIT®-Insect with multiple BEVS we were able to generate high-titer baculovirus that resulted in consistently higher protein expression in High Five™ and Sf9 cells compared to Cellfectin® II (Life Technologies).
Dr. Linda Lua
The University of Queensland - Protein Expression Facility
...However, I did find a gem: The TransIT®-2020 reagent from Mirus Bio LLC. I tested five or six breast cancer cell lines, and in general, my transfection efficiency was 5-10 fold higher with the TransIT®-2020 reagent than with the "standards" - Lipofectamine®...with essentially no cell death. I also saw, for the first time ever, true 100% transfection efficiency of HEK293 cells - every last cell on the plate, glowing bright GFP-green.
Nicole Perry
Kontrogianni Lab, University of Maryland
Our lab effectively carried out an RNAi screen against 45 mitochondrial candidate genes with TransIT-siQUEST® Transfection Reagent in HEK 293T cells. This work enabled us to identify a critical regulator (MCUR1) for calcium uptake in the mitochondria that regulates cellular metabolism. (Mallilankaraman, K et al. Nature Cell Biology. December 2012)
Dr. Karthik Mallilankaraman
Center for Translational Medicine - Temple University (Madesh Lab)
I was recently tasked with developing a CRISPR protocol for primary and bone-derived cell lines. TransIT-X2® was simple to use, 2-3 times better for transfection and much gentler on my cells than other products! I feel I have hit the jackpot and have already passed this exciting information on to my colleagues.
Dr. Joshua Chou
Harvard School of Dental Medicine
The TransIT-X2® Dynamic Delivery System performed better than our regular transfection reagent (PolyJet) for delivering DNA into the hard to transfect A549 cell line. TransIT-X2® was able to show protein expression compared to PolyJet which failed to produce detectable levels of protein containing V5 tag.
Dr. Jason Liggett and Kyung-Won Min
Baek Lab, University of Tennessee
The Ingenio® Electroporation Kit is routinely used in our lab to transfect induced pluripotent stem cells (iPSCs) via electroporation and yields extremely high transfection efficiency. The Ingenio® Kit is entirely compatible with the Amaxa® Nucleofector® and is also a much more cost effective solution.
Elizabeth Dominguez
Cellular Dynamics International (CDI)